Pharmacist Moms Group^™

Adam James, PharmD, and Chris Altman, PharmD, discuss renewed public scrutiny of thimerosal, its limited use in vaccines today, and how new guidance may affect pharmacists and patient confidence moving forward.

Debra Patt, MD, PhD, MBA, and Houston Holmes, MD, discuss the ramifications of the FDA's removal of REMS requirements for approved chimeric antigen receptor (CAR) T-cell (CAR T) therapies.

BCPPs can address behavioral health workforce shortages and advocate for expanded access and reimbursement amid evolving legislation and treatment landscapes.

Panelists discuss how initiating VMAT2 inhibitors for tardive dyskinesia requires careful consideration of factors like cost, patient tolerance, organ function, and drug interactions, emphasizing gradual dosing and shared decision-making to balance symptom control with adverse effect management in a personalized treatment approach.

Panelists discuss how personalizing tardive dyskinesia treatment involves a patient-centered approach that balances symptom impact, medication optimization, and comorbid psychiatric management—utilizing VMAT2 inhibitors alongside careful monitoring and collaboration among clinicians and pharmacists to tailor dosing and improve quality of life.

Keri Bates, PharmD, shares how the nomination validates years of hard work, highlights the deep relationships built with the community, and inspires continued growth and innovation.

Empowering pharmacy technicians enhances team efficiency, improves patient care, and fosters a positive work culture, driving pharmacy success in a competitive landscape.

These health care professionals are crucial to optimizing safety in medication therapy, addressing policy barriers, and the collaboration with others in the field.